Management of Dolichoectasia with Hypertension or Atherosclerosis
Antithrombotic Therapy Selection
- The American Heart Association/American Stroke Association recommends either antiplatelet or anticoagulant therapy for preventing recurrent ischemic events in patients with vertebrobasilar dolichoectasia who have experienced stroke or TIA, with a Class I, Level C-LD recommendation 1, 2
- Initiate aspirin 50-325 mg daily, clopidogrel 75 mg daily, or aspirin 25 mg plus extended-release dipyridamole 200 mg twice daily for long-term secondary prevention 3, 4
- For patients with recent minor stroke or high-risk TIA, start dual antiplatelet therapy within 12-24 hours and continue for 21-90 days, then transition to single antiplatelet therapy 3, 4
Blood Pressure Management
- The American Heart Association recommends aiming for a blood pressure of <140/90 mmHg in most patients to prevent recurrent ischemic events 5, 6
- Blood pressure reduction decreases stroke risk by 28% based on the PROGRESS trial using perindopril plus indapamide 5, 6
- ACE inhibitors or ARBs are preferred as they reduce stroke risk more effectively than other agents and provide vascular protection 5, 6
Atherosclerotic Risk Factor Management
- Initiate high-intensity statin therapy, such as atorvastatin 80 mg daily, based on the SPARCL trial showing a 16% relative risk reduction in all stroke and 22% reduction in ischemic stroke 5, 6
- Mandate complete smoking cessation as smoking increases ischemic stroke risk by 25-50% 5, 6